Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02138747 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
A Phase 4 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 4
- Development phase
- 376
- Enrollment target
NCT02138747 is a Phase 4 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 376 participants.
The verdict
NCT02138747, a Phase 4 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 376 participants
- Enrollment target
Study Summary
The purpose of this study was to assess tolerability of mirabegron compared to tolterodine ER in the treatment of participants with symptoms of Overactive Bladder (OAB) as well as the impact of treatment on micturition frequency and incontinence episodes.
Interventions
- DRUG Mirabegron
- DRUG Tolterodine ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2014-07-24 |
| Est. Completion | 2015-11-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02138747
The ClinicalTrials.gov registry entry for NCT02138747 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 376 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mirabegron is the first listed.
NCT02138747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02138747 about?
NCT02138747 is a clinical study titled "A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)". The purpose of this study was to assess tolerability of mirabegron compared to tolterodine ER in the treatment of participants with symptoms of Overactive Bladder (OAB) as well as the impact of treatment on micturition frequency and incontinence episodes.
What is the current status of trial NCT02138747?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 376 participants. The study started on 2014-07-24. Estimated completion is 2015-11-11.
What interventions are being tested in trial NCT02138747?
The interventions under investigation include: Mirabegron (DRUG), Tolterodine ER (DRUG).
Who is sponsoring clinical trial NCT02138747?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.